🇺🇸 FDA
Patent

US 10072086

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

granted A61KA61K2039/505A61K31/485

Quick answer

US patent 10072086 (Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2039/505, A61K31/485, A61K39/3955, A61K47/183